Nonsteroidal anti-inflammatory agents in neonates.

Area of Science:

• Neonatal Pharmacology
• Pediatric Therapeutics
• Prostaglandin System Biology

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for pain and fever in children and adults.
• NSAIDs are utilized in neonates primarily to close the ductus arteriosus.
• Acetaminophen (paracetamol), with weak NSAID activity, is also a frequent analgesic and antipyretic in neonates.

Purpose of the Study:

• To review the applications of various NSAIDs in the neonatal population.
• To examine the potential and real risks associated with NSAID use in neonates.
• To discuss the impact of prostaglandin system interference in this age group.

Main Methods:

• Comprehensive literature review of NSAID use in neonates.
• Analysis of the prostaglandin system's role in neonatal development and physiology.
• Evaluation of adverse effects and safety profiles of NSAIDs, including COX-2 inhibitors.

Main Results:

• NSAID use in neonates carries unique risks due to the prostaglandin system's critical role in development.
• Inhibition of prostaglandin synthesis can disrupt sleep, increase pulmonary hypertension, affect cerebral blood flow, renal function, thermoregulation, and hemostasis.
• NSAID exposure in utero and neonatally may adversely affect central nervous, cardiovascular, and renal system development.
• Selective cyclo-oxygenase type 2 (COX-2) inhibitors, while offering therapeutic flexibility, may not be safe for neonates and can induce a prothrombotic state.

Conclusions:

• The prostaglandin system's modulation in neonates via NSAIDs can impact multiple organ systems.
• Evidence suggests potential adverse effects of NSAIDs on neonatal organ system development.
• Further objective safety data are needed for parenteral NSAIDs, including COX-2 inhibitors, in neonates.